Publications

BibTex format

@article{Cortellini:2022:jnci/djac057,
author = {Cortellini, A and Gennari, A and Pommeret, F and Patel, G and Newsom-Davis, T and Bertuzzi, A and Viladot, M and Aguilar-Company, J and Mirallas, O and Felip, E and Lee, AJX and Dalla, Pria A and Sharkey, R and Brunet, J and Carmona-Garcia, M and Chester, J and Mukherjee, U and Scotti, L and Dolly, S and Sita-Lumsden, A and Ferrante, D and Van, Hemelrijck M and Moss, C and Russell, B and Segui, E and Biello, F and Krengli, M and Marco-Hernandez, J and Gaidano, G and Patriarca, A and Bruna, R and Roldan, E and Fox, L and Pous, A and Griscelli, F and Salazar, R and Martinez-Vila, C and Sureda, A and Loizidou, A and Maluquer, C and Stoclin, A and Iglesias, M and Pedrazzoli, P and Rizzo, G and Santoro, A and Rimassa, L and Rossi, S and Harbeck, N and de, Torre AS and Vincenzi, B and Libertini, M and Provenzano, S and Generali, D and Grisanti, S and Berardi, R and Tucci, M and Mazzoni, F and Lambertini, M and Tagliamento, M and Parisi, A and Zoratto, F and Queirolo, P and Giusti, R and Guid},
doi = {jnci/djac057},
journal = {Journal of the National Cancer Institute},
pages = {979--987},
title = {COVID-19 sequelae and the host proinflammatory response: an analysis from the oncovid registry},
url = {http://dx.doi.org/10.1093/jnci/djac057},
volume = {114},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundFifteen percent of patients with cancer experience symptomatic sequelae, which impair post–COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequelae.MethodsOnCovid recruited 2795 consecutive patients who were diagnosed with Severe Acute Respiratory Syndrome Coronavirus 2 infection between February 27, 2020, and February 14, 2021. This analysis focused on COVID-19 survivors who underwent a clinical reassessment after the exclusion of patients with hematological malignancies. We evaluated the association of inflammatory markers collected at COVID-19 diagnosis with sequelae, considering the impact of previous systemic anticancer therapy. All statistical tests were 2-sided.ResultsOf 1339 eligible patients, 203 experienced at least 1 sequela (15.2%). Median baseline C-reactive protein (CRP; 77.5 mg/L vs 22.2 mg/L, P < .001), lactate dehydrogenase (310 UI/L vs 274 UI/L, P = .03), and the neutrophil to lymphocyte ratio (NLR; 6.0 vs 4.3, P = .001) were statistically significantly higher among patients who experienced sequelae, whereas no association was reported for the platelet to lymphocyte ratio and the OnCovid Inflammatory Score, which includes albumin and lymphocytes. The widest area under the ROC curve (AUC) was reported for baseline CRP (AUC = 0.66, 95% confidence interval [CI]: 0.63 to 0.69), followed by the NLR (AUC = 0.58, 95% CI: 0.55 to 0.61) and lactate dehydrogenase (AUC = 0.57, 95% CI: 0.52 to 0.61). Using a fixed categorical multivariable analysis, high CRP (odds ratio [OR] = 2.56, 95% CI: 1.67 to 3.91) and NLR (OR = 1.45, 95% CI: 1.01 to 2.10) were confirmed to be statistically significantly associated with an increased risk of sequelae. Exposure to chemotherapy was associated with a decreased risk of sequelae (OR = 0.57, 95% CI: 0.36 to 0.91), whereas no associations with immune checkpoint
AU  - Cortellini,A
AU  - Gennari,A
AU  - Pommeret,F
AU  - Patel,G
AU  - Newsom-Davis,T
AU  - Bertuzzi,A
AU  - Viladot,M
AU  - Aguilar-Company,J
AU  - Mirallas,O
AU  - Felip,E
AU  - Lee,AJX
AU  - Dalla,Pria A
AU  - Sharkey,R
AU  - Brunet,J
AU  - Carmona-Garcia,M
AU  - Chester,J
AU  - Mukherjee,U
AU  - Scotti,L
AU  - Dolly,S
AU  - Sita-Lumsden,A
AU  - Ferrante,D
AU  - Van,Hemelrijck M
AU  - Moss,C
AU  - Russell,B
AU  - Segui,E
AU  - Biello,F
AU  - Krengli,M
AU  - Marco-Hernandez,J
AU  - Gaidano,G
AU  - Patriarca,A
AU  - Bruna,R
AU  - Roldan,E
AU  - Fox,L
AU  - Pous,A
AU  - Griscelli,F
AU  - Salazar,R
AU  - Martinez-Vila,C
AU  - Sureda,A
AU  - Loizidou,A
AU  - Maluquer,C
AU  - Stoclin,A
AU  - Iglesias,M
AU  - Pedrazzoli,P
AU  - Rizzo,G
AU  - Santoro,A
AU  - Rimassa,L
AU  - Rossi,S
AU  - Harbeck,N
AU  - de,Torre AS
AU  - Vincenzi,B
AU  - Libertini,M
AU  - Provenzano,S
AU  - Generali,D
AU  - Grisanti,S
AU  - Berardi,R
AU  - Tucci,M
AU  - Mazzoni,F
AU  - Lambertini,M
AU  - Tagliamento,M
AU  - Parisi,A
AU  - Zoratto,F
AU  - Queirolo,P
AU  - Giusti,R
AU  - Guida,A
AU  - Zambelli,A
AU  - Tondini,C
AU  - Maconi,A
AU  - Betti,M
AU  - Colomba,E
AU  - Diamantis,N
AU  - Sinclair,A
AU  - Bower,M
AU  - Ruiz-Camps,I
AU  - Pinato,DJ
DO  - jnci/djac057
EP  - 987
PY  - 2022///
SN  - 0027-8874
SP  - 979
TI  - COVID-19 sequelae and the host proinflammatory response: an analysis from the oncovid registry
T2  - Journal of the National Cancer Institute
UR  - http://dx.doi.org/10.1093/jnci/djac057
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000791476100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://academic.oup.com/jnci/article/114/7/979/6568023
UR  - http://hdl.handle.net/10044/1/103459
VL  - 114
ER  -

Download

Dr. David James PINATO

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)